Sanofi SA has identified thienopyrrolotriazine compounds reported to be useful for the treatment of multiple system atrophy, frontotemporal dementia, multiple sclerosis, amyotrophic lateral sclerosis, brain injury, Alzheimer’s and Parkinson’s disease.
Amgen Inc. has patented new quinazoline compounds acting as GTPase KRAS (G12D mutant) inhibitors and thus reported to be useful for the treatment of cancer.
Arizona State University (ASU) reported the receipt of a patent for a device with colorimetric sensors for measuring excreted ketones in a body fluid. Additional sensors may be incorporated to measure flow rate of the body fluid, barometric pressure, humidity, and chemicals such as oxygen and carbon dioxide present in the fluid, and a system to measure metabolic rate and respiratory quotient via oxygen consumption rate and carbon dioxide production rate.
University of California researchers saw publication of their patent application for a multimodal cryptographic bio-human machine interface (CB-HMI), which seamlessly translates the user's touch-based entries into encrypted biochemical, biophysica, and biometric indices.
Geode Therapeutics Inc. and Xtalpi Inc. have jointly developed stimulator of interferon genes protein (STING; TMEM173) modulators reported to be useful for the treatment of cancer, infections and autoimmune disease.
Research at MUSC Foundation for Research Development has led to the identification of small molecules targeting the voltage-dependent anion channel (VDAC) NADH binding pocket.
Recent Bristol Myers Squibb Co. patents describe new Toll-like receptor 9 (TLR9) antagonists reported to be useful for the treatment of inflammation, autoimmune disease, cancer, fibrosis, nonalcoholic steatohepatitis, chronic kidney disease, primary sclerosing cholangitis and idiopathic pulmonary fibrosis, among others.